Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acumen Pharmaceuticals Inc (NQ: ABOS )

2.370 +0.060 (+2.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acumen Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Stocks That Hit 52-Week Lows On Friday
On Friday, 111 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Citigroup (... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 92 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 29 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 81 stocks hit new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Grupo Aval Acciones (NYSE:AVAL) was the biggest company by market cap to set a... 
Via Benzinga
Earnings Scheduled For March 28, 2022
Companies Reporting Before The Bell • LGL Group (AMEX:LGL) is likely to report quarterly earnings at $0.10 per share on revenue of $7.20 million. 
Via Benzinga
More Specificity is What the Doctor Ordered
Photo by Steven HWG on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Surrozen (NASDAQ:SRZN) stock rose 33.14% to $9.64 during Tuesday's regular session. The company's market cap stands at $351.2 million. ZIOPHARM Oncology (... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 88 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Credit Suisse Group (NYSE:CS) was the largest, in terms of market cap... 
Via Benzinga
45 Stocks Moving In Tuesday's Mid-Day Session
Gainers IronNet, Inc. (NYSE: IRNT) shares jumped 50.4% to $25.06 after jumping over 23% on Friday. Mechel PAO (NYSE: MTL) shares jumped 32.6% to $4.2443. The company recently... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 21, 2022
Upgrades According to Seaport Global, the prior rating for KB Home (NYSE: 
Via Benzinga
The Past Week's Notable Insider Buys Include Krispy Kreme, Biotechs, SPACs And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Initial and secondary public offerings enticed insiders to... 
Via Benzinga
52 Weeks High And Low Article
Stocks that Broke Yearly Lows Tuesday Morning During Tuesday's morning trading, 87 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Highs And Lows: 10x... 
Via Benzinga
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,... 
Via Talk Markets
Exposures COVID-19 Product Safety
72 Biggest Movers From Yesterday
Gainers Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, including a 43% quarter-over-quarter revenue growth.... 
Via Benzinga
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2021
Upgrades Tudor Pickering upgraded the previous rating for Precision Drilling Corp (NYSE: 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share. Pop Culture Group Co., Ltd (... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Alzheimer's Biotech Acumen Pharmaceuticals Prices $125M IPO Soon After Biogen's Aduhelm Approval
Acumen Pharmaceuticals Inc has set the terms for its IPO to raise around $125 million to take ACU193, an antibody against amyloid-beta oligomers, to the end of phase 2 in... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback